Send to

Choose Destination
Cancer Lett. 2009 Mar 8;275(1):86-92. doi: 10.1016/j.canlet.2008.10.001. Epub 2008 Nov 1.

Suppression of androgen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells.

Author information

The Ben May Department for Cancer Research, The University of Chicago, 929 East 57th Street, CIS W325F, Chicago, IL 60637, USA.


The green tea polyphenol, (-)-epigallocatechin-3-gallate (EGCG), inhibits the development and progression of prostate cancer in TRAMP mice and in men. We examined the effects of EGCG on LNCaP human prostate cancer sublines 104-S, 104-R1 and R1Ad representing different progression stages of prostate cancer. EGCG suppressed cell proliferation, prostate specific antigen (PSA) expression, and AR transcriptional activity in the different LNCaP sublines. Intraperitoneal administration of EGCG also suppressed the growth of relapsing R1Ad tumors and decreased tumor-derived serum PSA. Effects of EGCG on tumor PSA expression have the potential to affect accurate monitoring of patient tumor burden by serum PSA measurements.

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center